Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Mar;6(2):165-180.
doi: 10.2217/cer-2016-0045. Epub 2017 Jan 13.

CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety

Affiliations
Free article
Meta-Analysis

CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety

Isabella Piassi Godói et al. J Comp Eff Res. 2017 Mar.
Free article

Abstract

Introduction: Dengue virus (DENV) is a serious global health problem. CYD-TDC (Dengvaxia®) was the first vaccine to gain regulatory approval to try and address this problem.

Aim: Summarize all available evidence on the immunogenicity, efficacy and safety of the CYD-TDV dengue vaccine.

Method: Meta-analysis and systematic review.

Results: The best and worst immunogenicity results were for DENV4 and DENV1, respectively. Vaccine efficacy of 60% was derived from studies with participants aged 2-16 years old, with DENV4 and DENV2 presenting the best and worst results, respectively. Erythema and swelling were more frequent with CYD-TDV. No differences were detected for systemic adverse events.

Conclusion: CYD-TDV showed moderate efficacy in children and adolescents. From the immunogenicity results in adults, we can expect satisfactory efficacy from vaccination in this population.

Keywords: CYD-TDV; dengue; meta-analysis; systematic review; vaccines.

PubMed Disclaimer